As filed with the Securities and Exchange Commission on March 1, 2023
Registration No. 333-264231
Registration No.
333-264465
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
POST-EFFECTIVE
AMENDMENT NO. 1
TO
FORM S-1
REGISTRATION STATEMENT UNDER THE SECURITIES
ACT OF 1933
Clarus Therapeutics
Holdings, Inc.
(Exact name of registrant as specified in its charter)
Delaware |
|
2836 |
|
85-1231852 |
(State or other jurisdiction of
incorporation or organization) |
|
(Primary Standard Industrial
Classification Code Number) |
|
(I.R.S. Employer
Identification Number) |
355 S. Grand Avenue, Suite 1450
Los Angeles, CA 90071
(847) 562-4300
(Address, including zip code, and telephone number,
including area code, of registrant’s principal executive offices)
Lawrence R. Perkins
Chief Restructuring Officer
Clarus Therapeutics Holdings, Inc.
355 S. Grand Avenue, Suite 1450
Los Angeles, CA 90071
(847) 562-4300
(Name, address, including zip code, and telephone
number, including area code, of agent for service)
Copies to:
Mitchell S. Bloom, Esq.
Marianne Sarrazin, Esq.
Goodwin Procter LLP
100 Northern Avenue
Boston, Massachusetts 02210
Tel: (617) 570-1000
Approximate date of commencement of proposed sale to the public:
Not applicable
If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant
to Rule 415 under the Securities Act of 1933 check the following box. ☐
If this Form
is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following
box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.
☐
If this Form is a post-effective amendment filed pursuant
to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier
effective registration statement for the same offering. ☐
If
this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller
reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer |
☐ |
Accelerated filer |
☐ |
Non-accelerated filer |
☒ |
Smaller reporting company |
☒ |
|
|
Emerging growth company |
☒ |
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 7(a)(2)(B) of the Securities Act. ☐
DEREGISTRATION OF UNSOLD SECURITIES
This Post-Effective Amendment No. 1, filed by Clarus
Therapeutics Holdings, Inc., a Delaware corporation, or the Registrant, relates to (i) the Registration Statement on Form S-1 (No. 333-264231),
originally filed with the U.S. Securities and Exchange Commission by the Registrant on April 11, 2022, as amended by Amendment No. 1 filed
on April 21, 2022 and Amendment No. 2 filed on April 25, 2022, or the Initial Registration Statement, and (ii) the Registration Statement
on Form S-1MEF (No. 333-264465) filed by the Registrant on April 25, 2022, or the Additional Registration Statement, and together with
the Initial Registration Statement, the Registration Statement, pertaining to the registration of 12,019,230 units which consist of either
(1) one share of the Registrant’s common stock and one Class A Warrant to purchase one share of common stock, or (2) one pre-funded
warrant (in lieu of common stock) and one Class A Warrant to purchase one share of common stock. The Registration Statement also registered
the common stock included in the units and the common stock issuable from time to time upon exercise of the Class A warrants and the pre-funded
warrants.
On September 5, 2022, the Registrant, and its wholly-owned
subsidiary Clarus Therapeutics, Inc., filed voluntary petitions for bankruptcy protection under Chapter 11 of Title 11 of the United States
Bankruptcy Code. The filing was made in the United States Bankruptcy Court for the District of Delaware (Case No. 22-10845), or the Chapter
11 Case.
In connection with the Chapter 11 Case, any and
all offerings pursuant to the Registration Statement have been terminated. In accordance with undertakings made by the Registrant in the
Registration Statement to remove from registration, by means of post-effective amendment, any of the shares that had been registered for
issuance that remain unsold at the termination of the offering, the Registrant hereby removes from registration all shares of the Registrant
registered but unsold under the Registration Statement as of the date hereof.
SIGNATURES
Pursuant to the requirements of the Securities Act
of 1933, the Registrant has duly caused this Post-Effective Amendment No. 1 to be signed on its behalf by the undersigned, thereunto duly
authorized, in the City of Los Angeles, in the State of California on March 1, 2023.
|
CLARUS THERAPEUTICS HOLDINGS, INC. |
|
|
|
|
/s/ Lawrence R. Perkins |
|
Name: |
Lawrence R. Perkins |
|
Title: |
Chief Restructuring Officer |
Clarus Therapeutics (NASDAQ:CRXT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Clarus Therapeutics (NASDAQ:CRXT)
Historical Stock Chart
From Sep 2023 to Sep 2024